세계의 강직성 척추염 치료 시장 - 규모, 점유율, 성장 분석 : 치료 유형별, 약제 유형별, 최종 사용자별, 지역별 산업 예측(2026-2033년)

Global Ankylosing Spondylitis Treatment Market size was valued at USD 3.34 Billion in 2024 and is poised to grow from USD 3.6 Billion in 2025 to USD 6.57 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).

The rising incidence of ankylosing spondylitis (AS) among young and middle-aged adults is significantly propelling market growth. AS, an autoimmune condition primarily affecting the spine and sacroiliac joints, can lead to debilitating pain and disability if untreated. Genetic predispositions, such as the HLA-B27 gene, contribute to varying incidence rates across regions, particularly in Europe, North America, and parts of Asia. Enhanced awareness and improved diagnostic procedures are facilitating earlier detection, increasing the patient population that requires effective long-term management. Biologic therapies, particularly tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) blockers, have emerged as effective treatments, specifically targeting inflammatory pathways. Ongoing research into next-generation biologics promises to expand treatment options, further driving investment and emphasizing the role of biologics in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ankylosing Spondylitis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ankylosing Spondylitis Treatment Market Segments Analysis

Global Ankylosing Spondylitis Treatment Market is segmented by Treatment Type, Drug Type, End-User and region. Based on Treatment Type, the market is segmented into NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Biologics (TNF Inhibitors, IL-17 Inhibitors), DMARDs (Disease-Modifying Anti-Rheumatic Drugs), Physical Therapy & Exercise and Others. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on End-User, the market is segmented into Hospitals & Clinics, Specialty Clinics and Home Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ankylosing Spondylitis Treatment Market

The rising global incidence of ankylosing spondylitis, especially among younger individuals, significantly contributes to the expansion of this market. As the number of diagnosed cases continues to grow, there is an escalating demand for effective treatment options. In response, healthcare providers and pharmaceutical companies are ramping up investments in the development of innovative drugs, advanced diagnostic tools, and comprehensive patient care approaches. This sustained focus on enhancing therapeutic solutions reflects the urgent need to meet the evolving healthcare challenges posed by ankylosing spondylitis, ultimately driving market growth and fostering improved patient outcomes.

Restraints in the Global Ankylosing Spondylitis Treatment Market

The Global Ankylosing Spondylitis Treatment market faces significant challenges, particularly in emerging regions, where limited awareness among patients and general practitioners contributes to delayed diagnoses. This lag in detection often leads to advanced disease progression and diminished treatment efficacy. Furthermore, a shortage of qualified rheumatologists, coupled with the lack of comprehensive initial screening initiatives, exacerbates these issues. As a result, these factors collectively hinder overall market growth, creating obstacles that must be addressed to improve patient outcomes and enhance the effectiveness of ankylosing spondylitis management.

Market Trends of the Global Ankylosing Spondylitis Treatment Market

The global ankylosing spondylitis treatment market is witnessing a significant shift towards biologics, with innovative therapies like TNF and IL-17 inhibitors transforming management strategies. This evolution is characterized by a growing preference among healthcare providers and patients for these targeted therapies, which offer improved efficacy and long-term disease control. The robust research and development landscape, coupled with an expanding portfolio of biosimilars, is further propelling market growth. Patients can expect enhanced quality of life and better therapeutic outcomes, positioning biologics as the cornerstone of future treatment paradigms in ankylosing spondylitis care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Analysis

Global Ankylosing Spondylitis Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
• Biologics (TNF Inhibitors, IL-17 Inhibitors)
• DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
• Physical Therapy & Exercise
• Others

Global Ankylosing Spondylitis Treatment Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Branded Drugs
• Generic Drugs

Global Ankylosing Spondylitis Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Specialty Clinics
• Home Care

Global Ankylosing Spondylitis Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Drug Type, End-User)
  • US
  • Canada
• Europe (Treatment Type, Drug Type, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Drug Type, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Drug Type, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Drug Type, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations